Symposia and Workshops

Topics

Symposium and Workshop Sessions are three hours each and Mini Symposia are scheduled for 75 minutes each.

Symposia and Workshops are scheduled for Monday, November 16, from 9:00 am to 12:00 noon and in the afternoon from 2:00 pm to 5:00 pm; Tuesday, November 17, from 9:00 am to 12:00 noon and in the afternoon from 2:00 pm to 5:00 pm; and Wednesday, November 18, from 9:00 am to 12:00 noon and in the afternoon from 2:00 pm to 5:00 pm. Mini Symposia are scheduled for Wednesday, November 18, in the afternoon from 2:00 pm to 5:00 pm. Times listed are in Central Standard Time.

The following learning levels have been identified for ACT educational offerings.

Foundational (Basic)
Focuses on core skills or fundamental understanding of a topic

Advanced
The converse of basic, if not basic then advanced

Practical
How to do it—procedures, design, reporting, use of tools, tips, tricks, experiences, and/or advice

Emerging
New, unusual, or uncommon techniques, modalities, ROA, guidance, tools/equipment (hardware and software), and/or changes to standard practice

Beyond the Vessel Wall: Translational Insights into Vascular Inflammation
Do You Hear What I Hear? Evaluating Otic and Vestibular Toxicity in Clinical Development
From China to the World: De-risking Nonclinical Safety Packages to Ensure Regulatory Acceptance
From Policy to Practice: Progress on the FDA’s 2025 Roadmap to Reduce Animal Use in Antibody Platform Development
Hot Topics
In Vivo Gene Therapies: Breakthrough Innovations, Regulatory Roadmaps, and Development Challenges
Invisible Ingredients, Critical Functions: The Risk Narrative around Excipients and PFAS
Managing Safety Signals and Clinical Holds: Case Studies across the Development Pipeline
Modernizing Drug Development: Advanced Translational Methodologies for CNS and PNS Risk Assessment
Next-Generation Liver Toxicity Assessment: Integrating Human-Relevant NAMs, AI, and Exposure Modeling
Overcoming the Blood-Brain Barrier and Translational Challenges in the Nonclinical Development of CNS Drugs
Safety and Regulatory Roadmap for Immune Engagers: Strategies to Translate Novel Modalities
Safety Assessment of Extractables and Leachables under the New ICH Q3E Guideline
The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development
The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift
The Role of Professional Judgment in Toxicology amidst the Rise of Artificial Intelligence and Computational Tools
The Versatile Toxicologist: How to Leverage Expertise into Opportunity
What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies